Paris - Delayed Quote EUR

Oncodesign Precision Medicine Société anonyme (ALOPM.PA)

0.7000

+0.0200

+(2.94%)

As of 4:51:45 PM GMT+1. Market Open.

Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers

DIJON, France, December 20, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces the reacquisition of the rights to its OPM-201 program in the treatment of Parkinson’s disease from Servier laboratories.

Business Wire 25 days ago

ALOPM.PA
+2.94%
OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

DIJON, France, October 22, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today confirms and details the final results of its Phase 1 clinical trial with OPM-101, its RIPK2 inhibitor and drug candidate administered orally to healthy volunteers, first reported on July 16, 2024. This clinical trial began in February 2023, the datab

Business Wire 2 months ago

ALOPM.PA
+2.94%
OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

DIJON, France, October 15, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced that a scientific abstract on its leading drug candidate, OPM-101, has been presented at the United European Gastroenterology (UEG) Week congress, October 12-15, 2024, in Vienna, Austria.

Business Wire 2 months ago

ALOPM.PA
+2.94%
OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation

DIJON, France, September 25, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced its financial results for the first half of 2024, approved by the Board of Directors on September 25, 2024.

Business Wire 3 months ago

ALOPM.PA
+2.94%
OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile

DIJON, France, July 16, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced positive results of phase 1 trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV).

Business Wire 5 months ago

ALOPM.PA
+2.94%
Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents

DIJON, France, May 15, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of Precision Medicine applications based on the Affilin® technology platform, announce the signature of a strategic collaboration agreement for

Business Wire 7 months ago

ALOPM.PA
+2.94%
Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine

DIJON, France, April 18, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, today announced that Degroof Petercam, a brokerage firm and investment bank, has initiated coverage of its shares.

Business Wire 8 months ago

ALOPM.PA
+2.94%
Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101

DIJON, France, April 17, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announced today that it has received notice of the grant of funding associated with the "i-Démo n°2" call for projects as part of the France 2030 plan. The aim of this call for projects is to develop industrial and service companies in growth markets that crea

Business Wire 8 months ago

ALOPM.PA
+2.94%
OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments

DIJON, France, March 26, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, has published its financial results for 2023, as approved by the Board of Directors on 26 March 2024.

Business Wire 9 months ago

ALOPM.PA
+2.94%
Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program

DIJON, France, February 29, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63 ; Mnemonic : ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announces today that it has received notification of the allocation of financial support from the Deep Tech Development Fund.

Business Wire 10 months ago

ALOPM.PA
+2.94%
Oncodesign Precision Medicine receives ERDF fund totalling €2.1 M for its COMETE program

DIJON, France, January 25, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnemonic : ALOPM) (Paris:ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, is pleased to announce that it has receive notification of the allocation of financial support from the European Regional Development Fund (ERDF) under the FEDER-SSE+ program for Bourgogne Franche-Comté and Massif du Jura 2021-2027 program (

Business Wire 11 months ago

ALOPM.PA
+2.94%

Performance Overview

Return	ALOPM.PA	CAC 40
YTD	-6.67%	+1.56%
1-Year	-65.52%	-0.51%
3-Year	-17.65%	+3.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oncodesign Precision Medicine Société anonyme (ALOPM.PA)

Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers

OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation

OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile

Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents

Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine

Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101

OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments

Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program

Oncodesign Precision Medicine receives ERDF fund totalling €2.1 M for its COMETE program

Performance Overview